Journal of Neurology

, Volume 261, Issue 6, pp 1187–1195

The screening of Alzheimer’s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials

  • Julien Dumurgier
  • Jean-Louis Laplanche
  • Francois Mouton-Liger
  • Pauline Lapalus
  • Sandrine Indart
  • Magali Prévot
  • Katell Peoc’h
  • Jacques Hugon
  • Claire Paquet
Original Communication


Polymorphism of the apolipoprotein E gene (APOE) plays a role in the level of neuropathological lesions and in drug response in Alzheimer’s disease (AD). The aim of this study was to investigate whether the selection of AD patients based on cerebrospinal fluid (CSF) biomarkers assessment may be biased by their APOE distribution. We studied the relationships between APOE genotype and CSF biomarkers levels in a total of 432 patients (AD, n = 244; non-AD, n = 188) explored for cognitive disorders. We studied the distribution of APOE genotypes among AD patient subgroups selected by various cut-offs of CSF biomarkers. Strategies of screening based on CSF Aβ1–42 lead to overselection of ε4/ε4 patients in the AD group. Screening based on tau levels did not change Apoe4 distribution in the AD group. CSF Aβ1–42 discriminated better AD patients with at least one ε4 than AD patients with no ε4. A strong allele-effect relationship was detected between APOE genotype and CSF amyloid-β (Aβ1–42) in AD patients. Selecting AD patients on CSF amyloid levels only may create an overselection of ε4/ε4 carriers, and might potentially bias the population of patients included in clinical trial studies.


Alzheimer’s disease Apolipoprotein E Biomarkers Cerebrospinal fluid Clinical trial design 

Supplementary material

415_2014_7335_MOESM1_ESM.doc (192 kb)
Supplementary material 1 (DOC 192 kb)


  1. 1.
    Duyckaerts C, Delatour B, Potier MC (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118:5–36CrossRefPubMedGoogle Scholar
  2. 2.
    (1998) Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer’s Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging 19:109–116Google Scholar
  3. 3.
    Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131–144CrossRefPubMedGoogle Scholar
  4. 4.
    Mouton-Liger F, Wallon D, Troussiere AC, Yatimi R, Dumurgier J, Magnin E et al (2013) Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical practice: a multicentric study. J Neurol 27:27Google Scholar
  5. 5.
    Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P et al (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9:1118–1127CrossRefPubMedGoogle Scholar
  6. 6.
    Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746CrossRefPubMedGoogle Scholar
  7. 7.
    Gauthier S, Dubois B, Feldman H, Scheltens P (2008) Revised research diagnostic criteria for Alzheimer’s disease. Lancet Neurol 7:668–670CrossRefPubMedGoogle Scholar
  8. 8.
    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Kozauer N, Katz R (2013) Regulatory innovation and drug development for early-stage Alzheimer’s disease. N Engl J Med 368:1169–1171CrossRefPubMedGoogle Scholar
  10. 10.
    Aisen PS, Vellas B, Hampel H (2013) Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. Nat Rev Drug Discov 12:15CrossRefGoogle Scholar
  11. 11.
    Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C et al (1998) Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 55:964–968CrossRefPubMedGoogle Scholar
  12. 12.
    Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278:1349–1356CrossRefPubMedGoogle Scholar
  13. 13.
    Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 26:32Google Scholar
  14. 14.
    Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol 10:241–252PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10:698–712CrossRefPubMedGoogle Scholar
  16. 16.
    Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M et al (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73:2061–2070PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Bizzarro A, Marra C, Acciarri A, Valenza A, Tiziano FD, Brahe C et al (2005) Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer’s disease. Dement Geriatr Cogn Disord 20:254–261CrossRefPubMedGoogle Scholar
  18. 18.
    de Oliveira FF, Bertolucci PH, Chen ES, Smith Mde A (2014) Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer’s disease. J Neurol Sci 336:103–108CrossRefPubMedGoogle Scholar
  19. 19.
    Rigaud AS, Traykov L, Latour F, Couderc R, Moulin F, Forette F (2002) Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer’s disease. Pharmacogenetics 12:415–420CrossRefPubMedGoogle Scholar
  20. 20.
    Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F et al (2010) Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study. CNS Drugs 24:163–176CrossRefPubMedGoogle Scholar
  21. 21.
    Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC et al (2012) Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11:241–249PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Grimmer T, Tholen S, Yousefi BH, Alexopoulos P, Forschler A, Forstl H et al (2010) Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer’s disease. Biol Psychiatry 68:879–884PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944CrossRefPubMedGoogle Scholar
  24. 24.
    Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S et al (2013) CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimers Dement 9:251–261PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Poli M, Gatta LB, Dominici R, Lovati C, Mariani C, Albertini A et al (2005) Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography. Clin Chem Lab Med 43:512–518CrossRefPubMedGoogle Scholar
  26. 26.
    Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172CrossRefPubMedGoogle Scholar
  27. 27.
    Pencina MJ, D’Agostino RB Sr, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11–21PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Bombois S, Duhamel A, Salleron J, Deramecourt V, Mackowiak MA, Deken V et al (2013) A new decision tree combining Abeta1–42 and p-Tau levels in Alzheimer’s diagnosis. Curr Alzheimer Res 10:357–364CrossRefPubMedGoogle Scholar
  29. 29.
    Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM et al (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78:47–54CrossRefPubMedGoogle Scholar
  30. 30.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of beta-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69:98–106CrossRefPubMedGoogle Scholar
  31. 31.
    Kanemaru K, Kameda N, Yamanouchi H (2000) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 54:1875–1876CrossRefPubMedGoogle Scholar
  32. 32.
    Nagga K, Gottfries J, Blennow K, Marcusson J (2002) Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1–42) in the differentiation between Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 14:183–190CrossRefPubMedGoogle Scholar
  33. 33.
    Morris HR, Waite AJ, Williams NM, Neal JW, Blake DJ (2012) Recent advances in the genetics of the ALS-FTLD complex. Curr Neurol Neurosci Rep 12:243–250CrossRefPubMedGoogle Scholar
  34. 34.
    Dumurgier J, Vercruysse O, Paquet C, Bombois S, Chaulet C, Laplanche JL et al (2013) Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting. Alzheimers Dement 9:406–413CrossRefPubMedGoogle Scholar
  35. 35.
    Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H et al (2007) Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem 101:1053–1059CrossRefPubMedGoogle Scholar
  36. 36.
    Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP et al (2013) Cerebrospinal fluid Abeta1–40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis 36:759–767PubMedGoogle Scholar
  37. 37.
    Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K (2004) APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 62:2116–2118CrossRefPubMedGoogle Scholar
  38. 38.
    Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ et al (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67:308–316PubMedCentralPubMedGoogle Scholar
  39. 39.
    Tapiola T, Pirttila T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H (2000) Relationship between apoE genotype and CSF beta-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease. Neurobiol Aging 21:735–740CrossRefPubMedGoogle Scholar
  40. 40.
    Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM (2009) CSF biomarkers in Alzheimer’s disease and controls: associations with APOE genotype are modified by age. J Alzheimers Dis 16:601–607PubMedGoogle Scholar
  41. 41.
    Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P et al (2013) Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging 34:1–12CrossRefPubMedGoogle Scholar
  42. 42.
    Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE et al (2003) Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer’s disease. Neurology 60:246–252CrossRefPubMedGoogle Scholar
  43. 43.
    Ghebremedhin E, Schultz C, Thal DR, Rub U, Ohm TG, Braak E et al (2001) Gender and age modify the association between APOE and AD-related neuropathology. Neurology 56:1696–1701CrossRefPubMedGoogle Scholar
  44. 44.
    Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP et al (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem 46:235–240CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Julien Dumurgier
    • 1
    • 2
  • Jean-Louis Laplanche
    • 3
  • Francois Mouton-Liger
    • 2
  • Pauline Lapalus
    • 1
  • Sandrine Indart
    • 1
  • Magali Prévot
    • 1
  • Katell Peoc’h
    • 3
  • Jacques Hugon
    • 1
    • 2
  • Claire Paquet
    • 1
    • 2
  1. 1.Memory Clinical Center CMRR Paris Nord Ile-de-FranceSaint Louis-Lariboisiere, Fernand Widal Hospital, AP-HPParisFrance
  2. 2.INSERM U942Saint Louis-Lariboisiere, Fernand Widal HospitalParisFrance
  3. 3.Department of BiochemistrySaint Louis-Lariboisiere, Fernand Widal Hospital, AP-HP, PRES Sorbonne-Paris CitéParisFrance

Personalised recommendations